Relief Therapeutics Holding AG (OTCQB: RLFTF) share price closed yesterday at $0.3600, up by 23.29%. During the session, Relief Therapeutics stock ranged in price from $0.3550 to $0.4100, as 35.19M of its shares were traded. RLFTF stock surged after NeuroRx released pivotal phase 2 data from their study in collaboration with Relief Therapeutics.
What was the collaboration for?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RLFTF focuses primarily on projects that are in clinical development that use molecules of natural origin (peptides and proteins) that have proven safety and efficacy in human clinical trials or who possess an excellent scientific rationale. At present, RLFTF is working to develop new treatments for a number of respiratory diseases. And the recent collaboration with NeuroRx is also a part of those efforts.
Read More
- The Top Cryptocurrency Stocks Flight in the Market for long-term
- Top 3 Cybersecurity Stocks You Should Keep on your Watch List
NeuroRx announced yesterday Phase 2b/3 results of the Intravenous ZYESAMI study in critically ill patients with COVID-19 for the treatment of respiratory failure in collaboration with Relief Therapeutics.
- After controlling for ventilation status and treatment site across all patients and treatment sites, ZYESAMI demonstrated a significant survival benefit beyond their primary endpoint of successful recovery from respiratory failure.
- Compared with those treated with mechanical or noninvasive ventilation at tertiary care hospitals, the 127 patients treated by High Flow Nasal Cannula (HFNC) have recovered clinically and statistically significantly from respiratory failure.
- In this group, 71% of ZYESAMI patients recovered successfully at 28 days as compared to just 48% for the placebo group, and 75% recovered successfully at 60 days as compared to only 55% for the placebo group.
- The survival rate for patients treated with ZYESAMI survived to day 60 reported in tertiary medical centers was 84% compared to 60% for those treated with placebo.
How will the RLFTF benefit from this?
Clinical trials in the U.S. are being conducted to determine whether two formulations of Relief Therapeutics (RLFTF) lead product candidate, RLF-100, are effective against COVID-19-induced respiratory failure. Therefore, working together to carry out trials like these will help the RLFTF advance its lead product.
